![Graeme Currie](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Graeme Currie
Corporate Officer/Principal presso PASITHEA THERAPEUTICS CORP.
Patrimonio netto: - $ in data 30/06/2024
Profilo
Graeme Martin Currie is currently the Chief Development Officer at Pasithea Therapeutics Corp.
Prior to his current position, he served as the Chief Executive Officer at Alpha-5 Integrin LLC from 2021 to 2022.
He also held the role of Director-Clinical Research at Gilead Sciences, Inc. and Vice President-Clinical Operations at PDL BioPharma, Inc. In addition, he served as the Chief Operating Officer at Rainier Therapeutics, Inc. from 2017 to 2019 and as the Chief Development Officer at Tolerion, Inc. from 2019 to 2021.
Currently, he is also the Chief Development Officer at Lytix Biopharma AS, a position he has held since 2021.
Dr. Currie obtained a doctorate degree from the University of Aston.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
29/04/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Posizioni attive di Graeme Currie
Società | Posizione | Inizio |
---|---|---|
PASITHEA THERAPEUTICS CORP. | Corporate Officer/Principal | 22/06/2022 |
Precedenti posizioni note di Graeme Currie
Società | Posizione | Fine |
---|---|---|
LYTIX BIOPHARMA | Corporate Officer/Principal | 01/06/2023 |
Alpha-5 Integrin LLC
![]() Alpha-5 Integrin LLC Pharmaceuticals: MajorHealth Technology Part of Pasithea Therapeutics Corp., Alpha-5 Integrin LLC is a company that develops monoclonal antibody for the treatment of amyotrophic lateral sclerosis and neurodegenerative diseases. The company is based in South San Francisco, CA. The CEO of the company is Graeme Currie. Alpha-5 Integrin was acquired by Pasithea Therapeutics Corp. on June 22, 2022 for $3.29 million. | Amministratore Delegato | 01/06/2022 |
Tolerion, Inc.
![]() Tolerion, Inc. Pharmaceuticals: MajorHealth Technology Tolerion, Inc. operates as a clinical-stage biopharmaceutical firm. It develops and commercializes therapeutics. The firm provides TOL-3034 and TOL-3052 to treat myasthenia gravis and neuromyelitis optica. The company was founded by Lawrence J. Steinman and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/01/2021 |
Rainier Therapeutics, Inc.
![]() Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Direttore operativo | 01/01/2019 |
PDL BIOPHARMA, INC. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Graeme Currie
University of Aston | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
LYTIX BIOPHARMA | Health Technology |
PASITHEA THERAPEUTICS CORP. | Health Technology |
Aziende private | 4 |
---|---|
PDL BioPharma, Inc.
![]() PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
Rainier Therapeutics, Inc.
![]() Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Health Technology |
Tolerion, Inc.
![]() Tolerion, Inc. Pharmaceuticals: MajorHealth Technology Tolerion, Inc. operates as a clinical-stage biopharmaceutical firm. It develops and commercializes therapeutics. The firm provides TOL-3034 and TOL-3052 to treat myasthenia gravis and neuromyelitis optica. The company was founded by Lawrence J. Steinman and is headquartered in South San Francisco, CA. | Health Technology |
Alpha-5 Integrin LLC
![]() Alpha-5 Integrin LLC Pharmaceuticals: MajorHealth Technology Part of Pasithea Therapeutics Corp., Alpha-5 Integrin LLC is a company that develops monoclonal antibody for the treatment of amyotrophic lateral sclerosis and neurodegenerative diseases. The company is based in South San Francisco, CA. The CEO of the company is Graeme Currie. Alpha-5 Integrin was acquired by Pasithea Therapeutics Corp. on June 22, 2022 for $3.29 million. | Health Technology |
- Borsa valori
- Insiders
- Graeme Currie